What is Tissium?
Tissium is a privately-owned medical technology company headquartered in Paris, France. The firm is dedicated to the rapid development and commercialization of a proprietary biopolymer platform designed to address a range of unmet clinical needs. Since its founding in 2013, Tissium has focused on leveraging its innovative technology to create solutions for various medical applications, positioning itself as a key player in the medtech sector.
How much funding has Tissium raised?
Tissium has raised a total of $259.5M across 6 funding rounds:
Series A
$27.4M
Series B
$42.8M
Debt
$8.2M
Series C
$59.1M
Series D
$53.8M
Other Financing Round
$68.1M
Series A (2016): $27.5M with participation from Omnes Venture Capital, Karista, Sofinnova Partners, and Cr�dit Mutuel Innovation
Series B (2020): $42.8M led by Bpifrance, Omnes Capital, M&L Investments, European Investment Fund, BNP Paribas Développement, ValQuest Partners, CM-CIC Innovation, Cap Décisif Management, and Sofinnova Partners
Debt (2020): $8.2M supported by BNP Paribas, Bpifrance, and CM-CIC Securities
Series C (2021): $59.1M featuring Sofinnova Partners and Cathay Health
Series D (2023): $53.8M backed by Sofinnova Partners, Mérieux Equity Partners, and Cathay Capital
Other Financing Round (2026): $68.1M with participation from European Investment Bank
Key Investors in Tissium
Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. They act as a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage.
Bpifrance
Bpifrance finances companies at each stage of their development with credit, guarantees, and equity, supporting them in innovation projects and internationally.
Cathay Capital
Cathay Capital operates as an international private equity firm specializing in cross-border investments that facilitate the expansion of middle-market enterprises across multiple continents.
What's next for Tissium?
With the recent major strategic investment and a substantial total funding amount of $259.5M, Tissium is well-positioned for its next phase of growth. The company's trajectory, marked by consistent capital raises including Series A, B, C, and D rounds, indicates a strong investor confidence in its biopolymer platform and its potential to disrupt the medical technology landscape. Future endeavors will likely focus on scaling operations, expanding clinical trials, and accelerating the commercialization of its innovative solutions, further solidifying its market presence and impact on patient care.
See full Tissium company page
